What is considered a “biotechnological process” under pre-AIA 35 U.S.C. 103(b)?
Pre-AIA 35 U.S.C. 103(b) provides a specific definition for a “biotechnological process.” According to the statute, it includes: A process of genetically altering or inducing a single- or multi-celled organism to: Express an exogenous nucleotide sequence Inhibit, eliminate, augment, or alter expression of an endogenous nucleotide sequence Express a specific physiological characteristic not naturally associated…
Read More